HBV感染合并慢性肾脏疾病抗病毒治疗研究进展

Advances in antiviral therapy for chronic kidney disease concomitant with HBV infection

乙型肝炎病毒(hepatitis B virus,HBV)感染是全球范围内的重大公共卫生问题,而HBV感染和慢性肾脏疾病(chronic kidney disease,CKD)之间存在一定关联,并且当CKD患者的肾脏病变处于不同阶段时,抗病毒治疗的药物选择和用药剂量存在差异。本文介绍了HBV感染与CKD的相关性,并重点综述了HBV感染合并CKD患者的抗病毒治疗药物选择和剂量调整等方面的进展,以及出现病毒学突破或持续的低病毒血症(low level viremia,LLV)等特殊情况下治疗策略的优化措施。

Hepatitis B virus(HBV) infection represents a major public health problem worldwide, and is accountable for chronic kidney disease(CKD). There is a difference in drug selection and dosing of antiviral therapy in CKD patients at different stages of the renal conditions. This review briefly describes the correlation between HBV infection and CKD,and focuses on the selection and dose adjustment of antiviral drugs in patients with HBV infection concomitant with renal disease, as well as the measures to optimize treatment strategies in special cases such as virological breakthrough or persistent low level viremia(LLV).